ALFA Finder| Management target | Revenue 20.0% FY27 |
|---|
| Revenue growth | 12% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margin at 27%; target range is 28-30%. |
| Order book | 33 active commercial molecules and 14 late-phase molecules in CMC pipeline. |
| Demand visibility | Over 90% pipeline visibility on FY27 targets. |
| Management confidence | Confident in executing long-term growth strategy and sustaining guidance. |
Growth
Revenue grew 12% YoY, EBITDA rose 18% to ₹148 Cr, and PAT increased 22% YoY. Material margin improved to 74% from 72%.
Outlook
Management maintains long-term revenue growth guidance of 15-20% and an EBITDA range of 28-30%. ₹263 Cr capex incurred this quarter.
Risks
Company notes standard forward-looking risks including regulatory approvals, technological changes, and market exposures.
Investor Presentation filed with BSE, NSE: SAILIFE. Summary written with AI assistance from the document.
Sai Life Science Ltd: key numbers
- Share price
- ₹1,910.70
- Market cap
- ₹40,618 Cr
- Revenue (annual)
- ₹2,192 Cr
- Net profit (annual)
- ₹348.9 Cr
- P/E (TTM)
- 108.0×Sector 43.8×
- Promoter holding
- 34.50%-0.03% QoQ
- FII holding
- 19.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Life Science Ltd
All →Sai Life Science Other Announcement
Sai Life Sciences filed a Crisil monitoring agency report on IPO proceeds utilisation for the quarter ended 30 September 2026. It is a routine SEBI-mandated compliance certificate with no transaction or business event.
Sai Life Science Earnings Call Transcript: Key Takeaways
Q2 revenue up 23% YoY, H1 up 17%, EBITDA margin steady at 28%. Management deflected on H2 figures, capacity timing and revenue visibility.
Sai Life Science Investor Presentation: Key Takeaways
H1 FY27 revenue ₹1,213 Cr (+17% YoY), EBITDA ₹335 Cr (28% margin), PAT ₹172 Cr (+19%). Q2 revenue ₹659 Cr (+23%). Strategy: integrated CRDMO, larger strategic pharma engagements, ₹621 Cr H1 capex.
Sai Life Science Results Update
Sai Life Sciences posted Q2 FY27 revenue growth of 23% YoY, with H1 PAT up 19% to ₹172 Cr. The company incurred ₹621 Cr capex in H1.
Sai Life Science Employee Stock Options
Sai Life Sciences allotted 108,005 ESOP equity shares, taking paid-up capital to Rs.21.26 Crore. No stated consideration means no event value.
Sai Life Science Management Change
Sai Life Sciences appointed three senior management personnel effective 5 November 2026. The appointees include Sidhartha Das as Senior Vice President and Head of Human Resources.